Lumos Diagnostics HoldingsLDXHF 31 Piotroski F-Score is 3 as of Jun. 24, 2026, which is 25% below its 10-year median of 4.00. GuruFocus rates LDXHF with a GF Score™ of 31/100 and a GF Value™ of $0.02 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Lumos Diagnostics Holdings ranks worse than 77.02% on this metric.
Warning Sign:
Piotroski F-Score of 3 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Lumos Diagnostics Holdings has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
The historical rank and industry rank for Lumos Diagnostics Holdings's Piotroski F-Score or its related term are showing as below:
LDXHF'
s Piotroski F-Score Range Over the Past 10 Years
Min: 3 Med: 4 Max: 5
Current: 3
During the past 4 years, the highest Piotroski F-Score of Lumos Diagnostics Holdings was 5. The lowest was 3. And the median was 4.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Lumos Diagnostics Holdings Piotroski F-Score Related Terms
Lumos Diagnostics Holdings Piotroski F-Score Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LDXHF vs ABT, SYK, MDT: Piotroski F-Score Comparison
For the Medical Devices subindustry, Lumos Diagnostics Holdings's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lumos Diagnostics Holdings Piotroski F-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lumos Diagnostics Holdings's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Lumos Diagnostics Holdings's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Lumos Diagnostics Holdings's current Net Income (TTM) was -7.18.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Lumos Diagnostics Holdings's current Cash Flow from Operations (TTM) was -9.33.
==> Negative ==> Score 0.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Lumos Diagnostics Holdings's return on assets of this year was -0.26764289. Lumos Diagnostics Holdings's return on assets of last year was -0.33801487.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Lumos Diagnostics Holdings's gearing of this year was 0.24931794. Lumos Diagnostics Holdings's gearing of last year was 0.27196356.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Lumos Diagnostics Holdings's current ratio of this year was 0.74136546. Lumos Diagnostics Holdings's current ratio of last year was 0.75703082.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Lumos Diagnostics Holdings's number of shares in issue this year was 680.183. Lumos Diagnostics Holdings's number of shares in issue last year was 493.637.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Lumos Diagnostics Holdings's gross margin of this year was 0.62951613. Lumos Diagnostics Holdings's gross margin of last year was 0.63767856.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Lumos Diagnostics Holdings's asset turnover of this year was 0.46203145. Lumos Diagnostics Holdings's asset turnover of last year was 0.43790078.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
1
+
0
+
1
+
0
+
0
+
0
+
1
=
3
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Lumos Diagnostics Holdings has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
Lumos Diagnostics Holdings (LDXHF) has a Piotroski F-Score of 3 as of Jun. 24, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Lumos Diagnostics Holdings and its competitors. This is 25% below median its historical median of 4.00. Over the past decade, Lumos Diagnostics Holdings' Piotroski F-Score has ranged from 3.00 to 5.00. According to the industry distribution chart, Lumos Diagnostics Holdings ranks #620 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 77%.
Is Lumos Diagnostics Holdings' Piotroski F-Score too high?
Lumos Diagnostics Holdings' current Piotroski F-Score of 3 is 25% below median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 5.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. Lumos Diagnostics Holdings' value of 3 is 40% below this industry median. Based on the distribution chart, Lumos Diagnostics Holdings ranks #620 out of 805 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Lumos Diagnostics Holdings has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lumos Diagnostics Holdings' Piotroski F-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Lumos Diagnostics Holdings ranks #620 out of 805 companies for Piotroski F-Score. This places Lumos Diagnostics Holdings in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Lumos Diagnostics Holdings' value of 3 is 40% below this benchmark. Historically, Lumos Diagnostics Holdings' own Piotroski F-Score has ranged from 3.00 to 5.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, Lumos Diagnostics Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lumos Diagnostics Holdings's current Piotroski F-Score of 3 is 40% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Lumos Diagnostics Holdings and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lumos Diagnostics Holdings's current Piotroski F-Score is 3, which is 25% below median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumos Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lumos Diagnostics Holdings (LDXHF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.08 — trading 300% above its estimated fair value. The current Piotroski F-Score is 3, which is 25% below median its 10-year median of 4.00 and 40% below the Medical Devices & Instruments industry median of 5.00. Lumos Diagnostics Holdings' overall GF Score™ is 31/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Lumos Diagnostics Holdings (LDXHF), the current Piotroski F-Score is 3 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lumos Diagnostics Holdings (LDXHF) Overvalued in 2026?
Based on GuruFocus' analysis, Lumos Diagnostics Holdings stock appears to be overvalued.
The current stock price of $0.08 is trading 300% above its estimated GF Value™ of $0.02.
GuruFocus considers Lumos Diagnostics Holdings to be Significantly Overvalued.
Key valuation signals for LDXHF:
Piotroski F-Score: 3 (25% below median its 10-year median of 4.00)
GF Value™: $0.02 vs. price of $0.08 (300% above fair value)
Industry Position: 40% below the Medical Devices & Instruments median (#620 of 805)
No single metric tells the full story. See the LDXHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services. The Company operates in two geographical regions, the United States and Australia and the majority of revenue is generated from the United States.
31GF Score
Get the complete analysis for LDXHF
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LDXHF has been successfully added to your 
